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ABSTRACT 
 
Attention-Deficit Hyperactivity Disorder (ADHD) has high heritability; however, studies of 
common variation account for <5% of ADHD variance. Using data from affected participants 
without a family history of ADHD, we sought to identify de novo variants that could account for 
sporadic ADHD. Considering a total of 128 families, two analyses were conducted in parallel: 
first, in 11 unaffected parent/affected proband trios (or quads with the addition of an unaffected 
sibling) we completed exome sequencing. Six de novo missense variants at highly conserved 
bases were identified and validated from 4 of the 11 families: the brain-expressed genes 
TBC1D9, DAGLA, QARS, CSMD2, TRPM2, and WDR83. Separately, in 117 unrelated probands 
with sporadic ADHD, we sequenced a panel of 26 genes implicated in intellectual disability (ID) 
and autism spectrum disorder (ASD) to evaluate whether variation in ASD/ID-associated genes 
were also present in participants with ADHD. Only one putative deleterious variant 
(Gln600STOP) in CHD1L was identified; this was found in a single proband. Notably, no other 
nonsense, splice, frameshift, or highly conserved missense variants in the 26 gene panel were 
identified and validated. These data suggest that de novo variant analysis in families with 
independently adjudicated sporadic ADHD diagnosis can identify novel genes implicated in 
ADHD pathogenesis. Moreover, that only 1 of the 128 cases (0.8%, 11 exome and 117 MIP 
sequenced participants) had putative deleterious variants within our data in 26 genes related to 
ID and ASD suggests significant independence in the genetic pathogenesis of ADHD as 
compared to ASD and ID phenotypes. 
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INTRODUCTION 
 
Attention deficit hyperactivity disorder (ADHD) is a childhood onset disorder characterized by 
symptoms of hyperactivity, inattention, and/or impulsivity, with an estimated pooled prevalence 
of 3-4% (Erskine et al., 2013). The heritability of ADHD has been estimated to be between 70-
90% (Stevenson, 1992; Levy et al., 1997; Faraone et al., 2012). Despite this strong evidence of 
inheritance of ADHD, genome-wide association studies (GWAS) of ADHD have not found any 
single nucleotide variant (SNV) to be associated with ADHD at the level of genome-wide 
significance (P < 5x10-8) (Zayats et al., 2016; Middeldorp et al., 2016; Stergiakouli et al., 2012; 
Neale et al., 2010). Familial and candidate gene studies have identified numerous significant 
associations with ADHD; however, SNVs in these genes were not significant in larger GWAS of 
unrelated participants, and do not account for large amounts of ADHD variance when considered 
in aggregate (<5%) (Franke et al., 2009; Hawi et al., 2015).  
 
Alternative to the use of GWAS and candidate gene studies of common SNVs, investigators 
have focused on rare SNVs identified through exome sequencing (Krumm et al., 2014), an 
approach that has been particularly fruitful for neurodevelopmental phenotypes. This approach 
was first used to identify pathogenic variants in genes likely causative for Mendelian-inherited 
disorders, such as Kabuki syndrome (Ng et al., 2010). Later, this emphasis on rare variants was 
extended to sporadic (occurring only in the proband, without evidence of inheritance from either 
parent) (Fischbach and Lord, 2010) and non-syndromic childhood psychiatric disorders, such as 
autism spectrum disorder (ASD) and intellectual disability (ID). Notably, these disorders - 
similar to ADHD – had not yielded genome-wide significant SNV associations (Zayats et al., 
2016; Middeldorp et al., 2016). Through use of familial data from trios (affected proband and 
parents) or quads (affected proband, unaffected sibling, parents), investigators identified 
numerous de novo mutational events in the proband that were potentially causative for ASD 
(O’Roak et al., 2011; O'Roak et al., 2012; Neale et al., 2012; Iossifov et al., 2012; Sanders et al., 
2012) or ID (Rauch et al., 2012; de Ligt et al., 2012). Proliferation of this approach to sporadic 
and non-syndromic ASD and ID has resulted in the identification of numerous candidate genes 
with potentially causative de novo mutations (Krumm et al., 2014). Twenty-six (26) of these 
candidate genes for ASD and ID currently compose a genetic panel used for rapid and efficient 
targeted exonic sequencing using molecular inversion probes (MIPs) (Coe et al., 2014). 
 
There is growing evidence of shared genetic etiology for numerous neuropsychiatric disorders. 
In particular, the Psychiatric Genomics Consortium (PGC) has identified genetic variants within 
L-type calcium channels, CACNA1C and CACNB2, which are significantly associated across the 
five major PGC phenotypes of study: ASD, ADHD, bipolar disorder, schizophrenia, and major 
depressive disorder (Smoller et al., 2013). In addition, there has been increasing scrutiny of the 
symptom overlap between ASD and ADHD (Mayes et al., 2011), with investigators suggesting 
candidate genes that may underlie risk for both disorders (Rommelse et al., 2010). Despite this 
speculation, few studies have yet evaluated the potential shared genetic etiology between ASD 
and ADHD specifically.  
 
In the present study, we applied the exome sequencing approach to familial data to identify rare, 
de novo SNVs that may be causative for sporadic and non-syndromic ADHD. In addition, we 
used MIP sequencing of 26 ASD and ID candidate genes in a large number of unrelated sporadic 
ADHD probands to determine whether these ASD and ID risk-genes are also associated with 
ADHD. 
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MATERIALS AND METHODS: 
 
Ethics Statement: 
The Institutional Review Boards of the University of Washington, University of California 
Irvine, Oregon Health and Science University (OHSU), and Michigan State University approved 
of this study. Written, informed consent was received from the parent or guardian of each minor.  
 
Selection of Participants: 
Families were recruited from the local community via public advertisements and mass mailings 
to parents of children in the target age range asking for volunteers for a study of attention, 
development, and ADHD, and specifying a need for healthy children as well as children with 
suspected or diagnosed ADHD. Identical procedures were followed at two different sites, one in 
Michigan and one in Oregon, thus covering two different geographic regions. An additional trio 
was identified at Washington and evaluated in the same manner, as outlined below. Through this 
process 846 children were identified who met our research criteria for ADHD (any subtype, 
using DSM-IV criteria). The definition of sporadic cases (below) was applied to this sample; 
17.0% met our definition of sporadic, yielding an N=155 for this study for. Eleven of those 
families were set aside for the sequencing described below, based on (a) availability of sufficient 
quality and quantity of DNA from both parents and (b) older parental age (see Supplemental 
Table 1 for a summary of the demographic and clinical characteristics of the 11 sporadic ADHD 
probands who underwent exome sequencing). The numbers and demographic and clinical 
features of the entire cohort, and the sporadic cases identified and studied here are described in 
Table 1. 
 
Procedure for Child Evaluation and Cohort Selection:  
Step 1. Selection of Cohort:  Interested families volunteered by contacting the study and then 
completed a multi-stage screening to identify participants for the study. Parents first completed a 
short screen to evaluate numerous exclusion criteria, including history of autism spectrum 
disorder, history of >1 non-febrile seizure; head injury with loss of consciousness > 1 minute, 
history of diagnosis with intellectual disability, and any long acting psychoactive medication that 
could not wash out for companion studies of cognitive functioning.  
 
Parents and teachers then completed nationally standardized rating scales (The Conners-III 
(Conners, 2014), the DuPaul ADHD Rating Scale (DuPaul, 2016), and the Strengths and 
Difficulties Questionnaire (SDQ, Goodman, 1997)). A parent completed a semi-structured 
clinical interview with a trained, masters-degree level clinician (KSADS-E (Orvaschel, 1994)). 
Inter-interviewer reliability with a gold standard trainer was satisfactory (k>.75 for all disorders 
discussed here). The clinician also briefly interviewed and observed the child. A full scale 
intellectual quotient (IQ) screening test (WISC-IV Vocabulary, Block Design, and Information 
(Wechsler, 1991)) and an academic screening test (WIAT-II Word Reading and Math Problem 
Solving (Wechsler, 2005)) were administered by different clinicians, who made detailed written 
notes on their behavioral observations.  
 
A team of experienced clinicians (a board certified child psychiatrist and a licensed clinical child 
psychologist) then reviewed all available information independently to arrive at a best estimate 
diagnostic profile for ADHD and all other child disorders, blind to all study hypotheses or 
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genetic data. Inter-clinician agreement was acceptable (k>.80 for all disorders discussed here). 
Disagreements were resolved by consensus. To be eligible, clinicians had to see cross-informant 
agreement at a minimal level i.e., (1) at least 3 symptoms of inattention or hyperactivity endorsed 
by both parent and teacher AND (2) at least T>60 on at least one nationally normed rating of 
ADHD symptoms by both reporters. They also had to show (3) impairment by at least one source 
(KSAD clinician rating or SDQ impairment at moderate or severe by at least one reporter). Once 
passing that screen-in, clinicians employed the “or” rule to count symptoms and conducted a 
further evaluation of rule outs, impairment, and other DSM criteria. 
 
Additional exclusion criteria were applied at that point, including appearance of autism spectrum 
disorder on the interview, estimated FSIQ < 80, history of ever had psychosis, or current major 
depressive episode (which made it difficult to evaluate symptoms of inattention), or failure of 
minimal convergence between parent and teacher ratings.  
  
Step 2. Parent ADHD and Sporadic Status: Determination of sporadic ADHD in the proband 
was evaluated by assessing each parent for ADHD on at least one of the following (a) a 
Structured Clinical Interview that included both a SCID-I (First et al., 2002) and modified 
KSADS  for adults on current and past symptoms of ADHD, (b)  the Conners Adult ADHD 
Rating Scale (CAARS (Conners, 2014)), and/or (c) the ADHD Rating Scale on current and 
childhood symptoms (DuPaul, 2016).  For each case, a parent provided a rating regarding history 
of ADHD in relatives of the child including the child’s siblings. If a parent was unavailable to 
complete an interview or ratings, the available parent rated the missing parent on the ADHD 
Rating Scale.  
 
Determination of Sporadic ADHD. Diagnosis of sporadic ADHD was then based on the 
following: 
a) Both parents denied history of confirmed or suspected ADHD in self, sibling, or parent 
(no child 1st or 2nd degree relative) on a Family Background Questionnaire; AND 
b) None of the child’s siblings had ever been diagnosed or treated for ADHD per parent 
report; AND 
c) Both parents scored < 6 symptoms of ADHD hyperactivity/impulsivity and < 6 
inattention on current and past ratings using the Barkley & Murphy Adult ADHD Rating 
Scale and the KSADS retrospective interview, and < T=65 on the Conners Adult ADHD 
Rating Scale. (In one case the ADHD RS and KSAD conflicted on our decision rule; the 
interview was used as the gold standard; in two cases the ADHD RS indicated no 
symptoms but the Conners > 65; we relied on the ADHD RS as the standard. In all other 
cases measures agreed on the case selection). The < 6 symptom cutoff was used in 
congruence with DSM-IV criteria (American Psychiatric Association), which were in 
force at the time this study was planned and data were collected. 
 
As noted, 155 families were identified as sporadic ADHD cases, 17.0% of the total cohort of 846 
ADHD cases. From these, 144 sporadic ADHD probands were sequenced for a panel of 26 genes 
of prior interest in ASD and ID, of which 117 passed quality control and were used in analyses. 
The remaining 11 families were tested for pilot exome sequencing to identify potential de novo 
SNVs responsible for sporadic ADHD. The 11 families selected for exome sequencing had an 
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average paternal age of 34.8 years (range 27.1 to 46.0 years); maternal average age was 33.1 
years (range 23.5 to 44.0 years).  
 
Exome Sequencing/De Novo Variant Identification in 11 Families with Sporadic ADHD:  
The NimbleGen Big Exome 2011 Library (EZ Exome v3 with approximately 64 Mb of target 
sequence) was used for exome sequencing of all 11 families’ DNA samples. FastQ files were 
aligned to the human genome reference sequence 19 (hg19) with the Burrows-Wheeler Aligner 
for the generation of BAM files (Li and Durbin, 2009). Realignment of regions with indels, 
recalibration of base qualities, and variant detection and calling was performed with the Genome 
Analysis Toolkit (GATK) UnifiedGenotyper to produce VCF files (McKenna et al., 2010). 
Variants sites of low quality and likely to be false positives were removed via the GATK Variant 
Quality Score Recalibrator. CNVs were separately called from exome sequence data by 
CoNIFER (Krumm et al., 2012). Annotation of variants was performed with SeattleSeq 138 
(http://snp.gs.washington.edu/). Relatedness between families was determined by comparing 
probands for relatedness up to the third degree (first cousins) using the software KING 
(Manichaikul et al., 2010).  
 
GEMINI was used to identify SNVs, CNVs, and indels present in the affected ADHD proband 
that were not present in the unaffected parents or sibling (if available) (Paila et al., 2013). Brain 
expression of the genes of the identified SNVs and CNVs was performed using the Human 
Protein Atlas. SNVs, CNVs, and indels were examined for evolutionary conservation through 
GERP, with a minimum cut-off of 3, indicative of high importance across species (Cooper et al., 
2005). Finally, these high-impact variants were filtered for presence in any database (NHLBI 
ESP Exome Variant Server, 1000 Genomes, or ExAC and, separately, the Database of Genomic 
Variants for indels). Variants not found in any known database were carried forward as de novo 
variants. As a secondary analysis, we considered the same classes of de novo variants, but 
relaxed the allele frequency to < 1% in the Exome Aggregation Consortium (ExAC) database if 
the same variant was found in a second affected proband, even when the occurrence in the 
second proband was not de novo.  
 
MIP Resequencing of ID/ASD Genes in 144 Unrelated, Sporadic ADHD Probands: 
Targeted molecular inversion probe (MIP) resequencing of 144 sporadic ADHD probands 
(excluding the 11 probands who already had data from exome sequencing) from OHSU and 
Michigan State University was performed for 26 candidate genes for ASD and ID (see Table 3 
in prior work by Coe et al and note that ARHGAP11A has subsequently been identified as a 
duplicated gene with no association with ASD/ID) (Coe et al., 2014), as previously described 
(O'Roak et al., 2012; 2014). In total, the coding sequence and splice-donor/splice-acceptor sites 
of the 26 candidate genes were targeted using 1,388 MIPs. Participant DNA was barcoded and 
sequenced using an Illumina HiSeq 2000. Quality control metrics for the MIPs used to sequence 
the genes implicated in ASD and ID are presented in Supplemental Table 2. 
 
Participants were filtered for quality control on the basis of the total percentage of MIPs with at 
least 20 reads (the minimum for variant calling). The sporadic ADHD probands were required to 
have a minimum of 75% MIP coverage at the threshold of 20x. This resulted in the inclusion of 
117 of 144 samples (81.25%) for analyses of GEMINI-determined loss-of-function stop-gain, 
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stop-loss, splice-acceptor, splice-donor, frameshift, and missense variants in the 26 candidate 
genes for ASD and ID. 
 
Validation of De Novo and MIP Sequencing Variants: 
All identified de novo SNVs identified in the sporadic ADHD families were separately validated 
using custom designed TaqMan assays (see Supplemental Table 3 for primer design). Similarly, 
SNVs and CNVs that were likely loss-of-function or high GERP missense variants in ASD or ID 
candidate genes were validated using Taqman assays (for SNVs) and quantitative PCR (qPCR, 
for CNVs). 
 
  
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved 8 
RESULTS 
 
Demographic and parental ADHD scale information for the 11 sporadic ADHD probands who 
underwent exome sequencing are presented in Table 2. Eight of the 11 exome sequenced 
families were European Ancestry (EA, 73%), while nine of the 11 probands were male (82%). 
The mean paternal age at birth of the ADHD proband was 34.8 years; notably, the father’s age 
was higher in the families for whom a de novo SNV was identified: 39.2 years as compared to 
32.3 years in families for whom no de novo SNV was found (one-sided t-test P=0.050). 
Additional clinical information about each of the 11 sporadic ADHD probands is presented in 
Supplemental Table 1. 
 
A total of 8 de novo missense SNVs were called in 4 of the 11 families with sporadic and non-
syndromic ADHD who underwent whole exome sequencing. Of these 8 de novo missense 
variants, 2 SNVs (in SARM1 and SPTBN2) in 2 unique families (4 and 6, respectively) did not 
subsequently validate in an orthogonal test (i.e., showed the reference, non-de novo SNV). The 6 
validated de novo missense SNVs were all expressed in the brain and found in 4 unique ADHD 
probands (Table 3). Single Taqman validated de novo missense SNVs were observed in 
TBC1D9His1179Tyr, and WDR83Gly127Arg in ADHD probands, but not parents or unaffected siblings 
(when available), in families 3 and 11, respectively. Families 4 and 10 each had 2 de novo and 
validated missense SNVs identified. In family 4, the sporadic ADHD proband carried 
DAGLAAsp1017His (rs199764983) and QARSCys471Tyr variants unobserved in family members. In 
family 10, the sporadic ADHD proband was observed to have both a CSMD2Ile891Val and 
TRPM2Arg687Cys (rs139554968) variant. Notably, 4 of the 6 validated de novo missense SNVs 
were not observed in any database. These results are summarized in Table 3. Additional SNVs 
that were identified as de novo in a proband but which were subsequently noted to be present in 
another proband, even if transmitted, and had MAF <1% are presented in Supplemental Table 
4.  
 
No CNVs or indels were identified as de novo and passed filtering criteria in the 11 families 
examined for sporadic ADHD. 
 
A MIP-based panel of 26 genes implicated in ASD and ID (Coe et al., 2014) was separately 
performed for the 117 probands with sporadic ADHD. Within the 26 genes, 3 total nonsense, 
splice, frameshift, or highly conserved missense variants were called among the 117 sporadic 
ADHD probands and the 11 sequenced trios and quads described above (see Table 4). Of these 3 
called variants, only 1 variant (CHD1LGln600STOP) in a single proband validated in TaqMan assay 
orthogonal testing. The other MIP called variants (ARHGAP11ATACA>TA frameshift and 
ADNPTT>TTGT frameshift) each subsequently showed homozygosity for the reference allele for all 
identified ADHD probands. The exomes of the 11 probands from the trios/quad tests were 
evaluated for variants in these same 26 genes and none were found.  Thus, only 1 of 128 ADHD 
probands (0.68%) had a putative deleterious variant identified in these 26 ASD/ID genes. 
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DISCUSSION: 
 
Previous studies of the genetic determinants of ADHD have not yielded SNVs or CNVs that are 
strongly associated with the ADHD phenotype (Neale et al., 2010; Stergiakouli et al., 2012; 
Franke et al., 2009). Given the high heritability of ADHD (Stevenson, 1992; Levy et al., 1997; 
Faraone et al., 2012), efforts have shifted from GWAS to alternative methods, such as statistical 
modeling of complex gene-by-gene/gene-by-environment interactions (Zuk et al., 2012) or the 
use of endophenotypes (Hawi et al., 2015) and/or continuous measures of ADHD severity 
(Groen-Blokhuis et al., 2014). In this work, we present an alternative view by performing the 
first known study to combine whole exome sequencing to identify rare, de novo variants of likely 
high impact (Eichler et al., 2010), with stringent phenotype classification to identify cases of 
sporadic and non-syndromic ADHD. 
 
Specifically in this work, we identified de novo missense variants present only in the 
sporadically affected proband that are possibly responsible for the sporadic ADHD observed in 
the proband. The 6 validated missense SNVs are each exceedingly rare (maximum allele 
frequency of 4.24x10-5), highly conserved, offering several additional possible candidates of 
study in the pathogenesis of sporadic ADHD. Notably, CSMD2 and TRPM2, both of which were 
identified in the same sporadic ADHD proband in Family 10, each have been reported in 
association with other psychiatric disorders; adult ADHD (Lesch et al., 2008) and schizophrenia 
(Håvik et al., 2011) for CSMD2, and bipolar disorder for TRPM2 (McQuillin et al., 2005; Jang et 
al., 2015).  Two additional de novo mutations identified in ADHD probands (see Supplemental 
Table 3) were found to have been transmitted to the probands in other families. The possibility 
that these are related to ADHD, but with incomplete penetrance and or additive effects, cannot 
be excluded.  
 
We MIP sequenced 26 genes associated with ASD and ID in 117 children with sporadic ADHD 
and evaluated their sequence from exomes in the 11 family probands to assess overlap in these 
genes with ADHD risk. These 26 genes are listed in Table 3 of work by Coe et al (Coe et al., 
2014); MIP coverage of these genes in our data is presented in Supplemental Table 1. In these 
128 children affected with ADHD (117 MIP sequenced and 11 exome sequenced), we identified 
and validated only 1 highly-conserved, called loss-of-function nonsense, splice, frameshift, or 
missense variant in the 26 ASD/ID genes, which was found in a single ADHD proband. This 
relative paucity of highly-damaging variants in these genes associated with ASD/ID suggest 
independent genetic pathways of pathogenesis for sporadic ADHD, as compared to the more 
frequently studied ASD/ID phenotypes (Krumm et al., 2014).  
 
Both common and rare variants are expected to contribute to the heritability of disease (Eichler 
et al., 2010). A large GWAS examining common SNVs have found significant associations with 
two L-type calcium channel genes, CACNA1C and CACNB2, when looking for phenotypic 
overlap between 5 psychiatric phenotypes (ASD, ADHD, bipolar disorder, major depressive 
disorder, and schizophrenia) as the outcome (Smoller et al., 2013). These and other prior results 
suggested a common genetic etiology in low penetrance risk variants between the disparate 
psychiatric disorders. Notably, prior study of psychiatric disease overlap did not specifically 
study ID (Smoller et al., 2013), nor have GWAS been performed on ID. Our work, which 
examined rare variants, suggests that high penetrance gene associations with sporadic ADHD do 
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not overlap with ASD and ID. However, as noted above, genes that may also be associated with 
schizophrenia and bipolar disorder (CSMD2 and TRPM2) did contain de novo mutations in 
sporadic ADHD probands. 
 
Several limitations of this study should be considered. First, our study did not identify any de 
novo CNVs in affected probands that could account for the occurrence of sporadic ADHD. Prior 
studies of ADHD have noted an enrichment of large CNVs in ADHD cases (Stergiakouli et al., 
2012; Elia et al., 2010), particularly in genes related to neurodevelopment (Williams et al., 
2010). Likely explanations for this paucity of CNVs are likely related to the difficulty in 
identifying large CNVs, which often span intergenic regions not captured by exome and MIP 
probes (Krumm et al., 2012). Second, our study was composed of two aims, which occurred 
independently and temporally parallel to each other: to identify de novo variants in sporadic 
ADHD probands and to exclude the possibility of overlap with genes implicated in ASD and ID. 
As we used an existing gene panel for ASD and ID (Coe et al., 2014); we did not have the 
capability to examine the unique genes implicated in sporadic ADHD in the 117 independent 
samples used to exclude genetic overlap with ASD and ID. Third, it is notable that while nine of 
the 11 families studied were EA, two of the four families in which de novo missense SNVs were 
identified were non-EA (see Table 2). Finally, our analyses of de novo variation included only 
11 families. Our study was also underpowered to detect recurrent de novo variants in the same 
gene; this phenomena has been noted to have only occurred 3 times thus far for ASD/ID (in 
genes CHD8, NTNG1, and SCN2A) after the sequencing of several thousand probands (Krumm 
et al., 2014).  
 
In summary, ADHD is a prevalent disease of childhood (Thomas et al., 2015) that has been 
reported to cause an approximate 2-fold increased mortality rate ratio in a recent large cohort 
study (Dalsgaard et al., 2015) in addition to the other challenges the affected patients face. 
Despite the importance of ADHD, little is yet known of the specific genetic factors that influence 
its pathogenesis (Neale et al., 2010; Hawi et al., 2015). Within this context, we have performed 
the first known exome sequencing analysis of sporadic (non-inherited) ADHD and identified six 
candidate genes with de novo missense SNVs. We also report the novel finding that the genetic 
etiology of sporadic ADHD appears to be independent of ASD and ID, contradicting past 
findings from GWAS. These results emphasize the importance of identifying and evaluating 
specific genetic predictors of ADHD, to better understand the pathogenesis of this prevalent and 
morbid disorder of childhood. 
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Description of Appendices: Supplemental material includes four tables. Supplemental Table 4 
describes clinical and demographic information for the 11 sporadic ADHD probands chosen for 
trio or quad exome sequencing for discovery of de novo variants potentially causative for 
ADHD. Supplemental Table 2 describes the quality control metrics for the 26 genes associated 
with ASD or ID that were MIP sequenced in our study. Supplemental Table 3 describes the 
primer design for validation of SNVs and CNVs identified in the study. Supplemental Table 4 
describes SNVs that were identified as de novo but were present in other non-family members 
(e.g., SNV identified in ADHD proband in family 2, but same SNV is also present in the father 
in family 3).   
 
 
Web Resources: The URLs for data presented herein are as follows: 
1000 Genomes Browser, http://www.1000genomes.org/1000-genomes-browsers 
Database of Genomic Variants, http://dgv.tcag.ca/dgv/app/home 
ExAC Browser, http://exac.broadinstitute.org/  
Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS/  
GEMINI, https://gemini.readthedocs.org/en/latest/ 
Human Protein Atlas, http://www.proteinatlas.org/ 
SeattleSeq Annotation 138, http://snp.gs.washington.edu/SeattleSeqAnnotation138/  
UCSC Genome Browser, http://genome.ucsc.edu 
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Table 1. Summary of the selected sporadic ADHD cases for MIP and exome sequencing versus total cohort. 
 Excluded Familial 
ADHD Cases 
(N=691) 
Sporadic ADHD Cases 
MIP Sequenced 
(N=144) 
Sporadic ADHD Cases Trio 
or Quad Exome Sequenced 
(N=11) 
Male, % 70% 67% 82% 
Age, years 9.9 10.1 9.8 
Full scale IQa 105 107 106 
Word reading scorea 104 101 111 
Family income, thousands, $ 64.1 64.3 101 
Lifetime ODD diagnosisb, % 24% 21% 18% 
Lifetime anxiety diagnosisb, % 30% 35% 27% 
Lifetime mood disorderb, % 12% 14% 0% 
ADHD Hyperactivity T-Scorec 70 65 72 
ADHD Inattention T-Scorec 74 70 79 
Abbreviations: ADHD = attention-deficit hyperactivity disorder; IQ = intellectual quotient; ODD = oppositional defiant disorder. 
a IQ and reading assessment are described in the text; these are standard scores with a mean of 100 and standard deviation of 15.  
b Comorbid disorders are identified by the KSADS interview and diagnostic team review as described in the text.  
c ADHD Rating Scale Parent rating T-scores have a mean of 50 and standard deviation of 10.   
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Table 2. Demographic and parental ADHD characteristic comparison among 11 exome sequenced families. 
 
 European Ancestry (n), % Male Proband (n), % Mean Paternal Age 
11 families 9 (82%) 9 (82%) 34.8 years 
   4 families with de novo SNV 2 (50%) 4 (100%) 39.2 years 
   7 families without de novo SNV 7 (100%) 5 (71%) 32.3 years 
Abbreviations: ADHD = attention-deficit hyperactivity disorder; SNV = single nucleotide variant.  
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Table 3. Summary of de novo SNVs identified by trio or quad sequencing of sporadic ADHD in 11 families. 
 
Gene Affected Variant Chr:Positiona rsID GERP MAFb Brain Expression c Study Family 
Validated de novo missense SNVs 
TBC1D9 His1179Tyr 4:141543615 None 5.01 0 Yes 3 
DAGLAd Asp1017His 11:61511880 rs199764983 4.14 4.24x10-5 Yes 4 
QARSe Cys471Tyr 3:49137057 None 5.86 0 Yes 4 
CSMD2f Ile891Val 1:34190974 None 3.28 0 Yes 10 
TRPM2g Arg687Cys 21:45819235 rs139554968 4.19 3.34x10-5 Yes 10 
WDR83 Gly127Arg 19:12781425 None 4.51 0 Yes 11 
Abbreviations: Chr = chromosome; GERP = genomic evolutionary rate profiling; MAF = minor allele frequency; N/A = not available 
a Position based on hg19 build. 
b Minor allele frequency from ExAC pooled data. 
c Brain tissue gene expression data from the Human Tissue Atlas. 
d A DAGLA CNV has been implicated in autosomal dominant spinocerebellar ataxia 20 (OMIM 608687) based on a 260 kb 
duplication on chromosome 11q12.2-11q12.3 (Knight et al., 2004; Coutinho et al., 2006).  
e QARS rare variants have been implicated in two cases of autosomal recessive progressive microcephaly with seizures and 
cerebral/cerebellar atrophy (OMIM 603727 and (Zhang et al., 2014).  
f CSMD2 common variants have previously been associated with adult ADHD (Lesch et al., 2008) and schizophrenia (Håvik et al., 
2011).   
g TRPM2 common variants have previously been associated with bipolar disorder (McQuillin et al., 2005; Jang et al., 2015).  
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Table 4. Called loss of function or highly conserved missense variants in 26 gene autism spectrum disorder/intellectual 
disability MIP panel considering 117 ADHD probands (excluding the 11 probands who underwent whole exome sequencing). 
 
Gene  Variant Chr:Positiona rsID GERP MAFb #Affected ADHD Probands #Validated/N 
ARHGAP11A Frameshift (TACA>TA) 
15:32917411- 
32917415 None 4.95 0 1 0/1 
CHD1L Gln600STOP 1:146765310 rs149664186 5.27 
 
0.00034 
 
1 1/1 
ADNP Frameshift (TT>TTGT) 
20:49510414- 
49510416 None 4.81 0 1 0/1 
a Position based on hg19 build. 
b Minor allele frequency from ExAC pooled data 
